S&P 500   4,280.68 (+0.14%)
DOW   33,589.47 (+0.12%)
QQQ   353.94 (-0.31%)
AAPL   168.90 (-0.90%)
MSFT   310.44 (-0.75%)
META   298.28 (+0.18%)
GOOGL   130.29 (-0.19%)
AMZN   123.60 (-1.89%)
TSLA   241.94 (+0.60%)
NVDA   425.59 (+0.21%)
NIO   8.62 (+1.89%)
BABA   84.63 (-1.81%)
AMD   100.00 (+1.97%)
T   14.97 (+0.67%)
F   12.29 (-0.81%)
MU   64.77 (-5.04%)
CGC   0.82 (-7.49%)
GE   111.18 (+0.26%)
DIS   80.39 (+0.61%)
AMC   7.50 (-0.92%)
PFE   31.93 (-0.53%)
PYPL   57.48 (+0.24%)
NFLX   375.04 (-0.68%)
S&P 500   4,280.68 (+0.14%)
DOW   33,589.47 (+0.12%)
QQQ   353.94 (-0.31%)
AAPL   168.90 (-0.90%)
MSFT   310.44 (-0.75%)
META   298.28 (+0.18%)
GOOGL   130.29 (-0.19%)
AMZN   123.60 (-1.89%)
TSLA   241.94 (+0.60%)
NVDA   425.59 (+0.21%)
NIO   8.62 (+1.89%)
BABA   84.63 (-1.81%)
AMD   100.00 (+1.97%)
T   14.97 (+0.67%)
F   12.29 (-0.81%)
MU   64.77 (-5.04%)
CGC   0.82 (-7.49%)
GE   111.18 (+0.26%)
DIS   80.39 (+0.61%)
AMC   7.50 (-0.92%)
PFE   31.93 (-0.53%)
PYPL   57.48 (+0.24%)
NFLX   375.04 (-0.68%)
S&P 500   4,280.68 (+0.14%)
DOW   33,589.47 (+0.12%)
QQQ   353.94 (-0.31%)
AAPL   168.90 (-0.90%)
MSFT   310.44 (-0.75%)
META   298.28 (+0.18%)
GOOGL   130.29 (-0.19%)
AMZN   123.60 (-1.89%)
TSLA   241.94 (+0.60%)
NVDA   425.59 (+0.21%)
NIO   8.62 (+1.89%)
BABA   84.63 (-1.81%)
AMD   100.00 (+1.97%)
T   14.97 (+0.67%)
F   12.29 (-0.81%)
MU   64.77 (-5.04%)
CGC   0.82 (-7.49%)
GE   111.18 (+0.26%)
DIS   80.39 (+0.61%)
AMC   7.50 (-0.92%)
PFE   31.93 (-0.53%)
PYPL   57.48 (+0.24%)
NFLX   375.04 (-0.68%)
S&P 500   4,280.68 (+0.14%)
DOW   33,589.47 (+0.12%)
QQQ   353.94 (-0.31%)
AAPL   168.90 (-0.90%)
MSFT   310.44 (-0.75%)
META   298.28 (+0.18%)
GOOGL   130.29 (-0.19%)
AMZN   123.60 (-1.89%)
TSLA   241.94 (+0.60%)
NVDA   425.59 (+0.21%)
NIO   8.62 (+1.89%)
BABA   84.63 (-1.81%)
AMD   100.00 (+1.97%)
T   14.97 (+0.67%)
F   12.29 (-0.81%)
MU   64.77 (-5.04%)
CGC   0.82 (-7.49%)
GE   111.18 (+0.26%)
DIS   80.39 (+0.61%)
AMC   7.50 (-0.92%)
PFE   31.93 (-0.53%)
PYPL   57.48 (+0.24%)
NFLX   375.04 (-0.68%)
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$11.70
0.00 (0.00%)
(As of 09:45 AM ET)
Compare
Today's Range
$11.57
$11.76
50-Day Range
$11.52
$13.98
52-Week Range
$4.82
$14.92
Volume
6,296 shs
Average Volume
159,900 shs
Market Capitalization
$575.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.8% Upside
$18.00 Price Target
Short Interest
Bearish
5.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

815th out of 975 stocks

Pharmaceutical Preparations Industry

385th out of 459 stocks


ALPN stock logo

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Price History

ALPN Stock News Headlines

H.C. Wainwright Keeps Their Buy Rating on Alpine Immune Sciences (ALPN)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Analyst Expectations for Alpine Immune Sciences's Future
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Alpine Immune Sciences (NASDAQ: ALPN)
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Company Calendar

Last Earnings
8/14/2023
Today
9/28/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+53.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-57,760,000.00
Net Margins
-201.07%
Pretax Margin
-199.19%

Debt

Sales & Book Value

Annual Sales
$30.06 million
Book Value
$3.90 per share

Miscellaneous

Free Float
28,390,000
Market Cap
$575.64 million
Optionable
Not Optionable
Beta
1.27
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 55)
    Exec. Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 52)
    Ph.D., Pres and Head of R&D
    Comp: $751.2k
  • Mr. Paul Rickey (Age 44)
    Sr. VP, CFO, Treasurer & Sec.
    Comp: $577.1k
  • Dr. Wayne R. Gombotz (Age 64)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corp. Communications
  • Dr. Remy Durand Ph.D. (Age 38)
    Chief Bus. Officer
  • Dr. Andrew Seth Sandler M.D. (Age 58)
    Chief Medical Officer













ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price forecast for 2023?

5 analysts have issued 12 month price targets for Alpine Immune Sciences' shares. Their ALPN share price forecasts range from $15.00 to $22.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2023?

Alpine Immune Sciences' stock was trading at $7.35 on January 1st, 2023. Since then, ALPN shares have increased by 59.2% and is now trading at $11.70.
View the best growth stocks for 2023 here
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.11. The biotechnology company earned $8.59 million during the quarter, compared to analysts' expectations of $8.08 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 33.44% and a negative net margin of 201.07%.

What ETF holds Alpine Immune Sciences' stock ?

AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio.

What other stocks do shareholders of Alpine Immune Sciences own?
What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.78%), Great Point Partners LLC (7.01%), BlackRock Inc. (4.76%), Geode Capital Management LLC (1.29%), State Street Corp (1.19%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $11.70.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $575.64 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

The company employs 126 workers across the globe.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -